iBio (IBIO) Competitors

Benitec Biopharma (NASDAQ:BNTC) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking.

Do insiders & institutionals have more ownership in BNTC or IBIO?

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 0.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor BNTC or IBIO?

Benitec Biopharma received 186 more outperform votes than iBio when rated by MarketBeat users. Likewise, 64.73% of users gave Benitec Biopharma an outperform vote while only 42.86% of users gave iBio an outperform vote.

Company	Underperform	Outperform
Benitec Biopharma	Outperform Votes 189 64.73%	Underperform Votes 103 35.27%
iBio	Outperform Votes 3 42.86%	Underperform Votes 4 57.14%

Does the media favor BNTC or IBIO?

In the previous week, Benitec Biopharma had 1 more articles in the media than iBio. MarketBeat recorded 1 mentions for Benitec Biopharma and 0 mentions for iBio. Benitec Biopharma's average media sentiment score of 0.59 beat iBio's score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Benitec Biopharma	Positive
iBio	Neutral

Do analysts prefer BNTC or IBIO?

Benitec Biopharma currently has a consensus price target of $22.60, indicating a potential upside of 106.96%. iBio has a consensus price target of $4.30, indicating a potential upside of 61.05%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Benitec Biopharma is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
iBio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation & earnings, BNTC or IBIO?

Benitec Biopharma has higher earnings, but lower revenue than iBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	1,440.89	-$21.75M	N/A	N/A
iBio	$225K	108.44	-$24.91M	N/A	N/A

Is BNTC or IBIO more profitable?

iBio's return on equity of -90.06% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-90.14%	-75.25%
iBio	N/A	-90.06%	-41.02%

Which has more risk & volatility, BNTC or IBIO?

Benitec Biopharma has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, iBio has a beta of -3.33, meaning that its share price is 433% less volatile than the S&P 500.

Summary

Benitec Biopharma beats iBio on 13 of the 16 factors compared between the two stocks.